SPRX-3 Drug Patent Profile
When do Sprx-3 patents expire, and what generic alternatives are available?
Sprx-3 is a drug marketed by Solvay and is included in one NDA.
The generic ingredient in SPRX-3 is phendimetrazine tartrate. There is one drug master file entry for this compound. Twelve suppliers are listed for this compound. Additional details are available on the phendimetrazine tartrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sprx-3
A generic version of SPRX-3 was approved as phendimetrazine tartrate by CHARTWELL on October 30th, 1991.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for SPRX-3?
- What are the global sales for SPRX-3?
- What is Average Wholesale Price for SPRX-3?
Summary for SPRX-3
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 11 |
| Patent Applications: | 547 |
| DailyMed Link: | SPRX-3 at DailyMed |
US Patents and Regulatory Information for SPRX-3
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Solvay | SPRX-3 | phendimetrazine tartrate | CAPSULE;ORAL | 085897-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
